Om Megashree Pharmaceuticals Limited (OMPL) has officially announced the issuance of its Initial Public Offering (IPO) for Nepalese citizens working abroad from 21st Magh to 5th Falgun, 2081. The application period will not be extended beyond the early closing date.
Key Details of the IPO
- IPO Overview:
- The company’s total issued capital is Rs. 60 Crores, of which 30% (18,00,000 shares worth Rs. 18 Crores) is being offered to the public.
- Of this, 10% (1,80,000 shares) has been specifically allocated for Nepalese citizens employed abroad.
- Allocations:
- 5% (90,000 shares) are reserved for mutual funds.
- 3% (54,000 shares) are allocated for the company’s employees.
- The remaining 14,76,000 shares will be available to the general public.
- Application Limits:
- Investors can apply for a minimum of 10 shares and a maximum of 10,000 shares.
- Issue Manager: Prabhu Capital Limited
- The IPO result of Om Megashree Pharmaceuticals will be published within 10 days after the IPO closes.
Utilization of Capital Raised from This IPO Issuance:
Details of Senior Managerial Level Officers of Om Megashree Pharmaceuticals:
Credit Rating
About Om Megashree Pharmaceuticals
Om Megashree Pharmaceuticals, established in 2017 and converted to a public limited company in 2022, is a Nepalese company producing high-quality medicines. Its modern manufacturing facility in Jugedi-29, Chitwan, covers 22,044 sq. ft. and uses advanced technology to make human and veterinary care medicines, including tablets, capsules, syrups, creams, and eye/ear drops. Focused on Cardio-diabetics, neuropsychiatric, and other critical areas, the company aims to provide affordable, quality medicines globally, driven by its mission: “Your health is our concern.”